All Videos - PainCast

(L) Dr. Tim Deer – Creating the Singularity where is neuromodulation taking us – Video Hero Slider

Watch Now

NEWEST VIDEO

Watch Now

Creating the Singularity where is neuromodulation taking us

growth becomes exponential and irreversible. He challenges the idea of hardware unification across companies and instead reframes singularity as a coming wave of revolutionary innovation. Highlighting breakthroughs in neurorestoration, brain-computer interfaces, optogenetics, and AI-driven performance enhancement, he envisions a future where neuromodulation reshapes mobility, cognition, and memory. From paralyzed patients walking again to implantable memory-enhancing technologies, Dr. Deer outlines how these advancements could transform pain management, disability care, and human potential—while cautioning about ethical implications and the “tribal” limitations of device brand loyalty.

(L) Dr. Leonardo Kapural – High Frequency Stimulation Data Matters – Video Hero Slider

High Frequency Stimulation Data Matters

This presentation explores the clinical value of 10 kHz high-frequency spinal cord stimulation (HF-SCS) for treating various chronic pain conditions, including non-surgical refractory back pain, diabetic peripheral neuropathy, and chronic abdominal pain. The speaker reviews pivotal studies demonstrating long-term pain relief and functional improvements, highlighting data integrity, trial design, and superior outcomes compared to traditional paresthesia-based systems. Additionally, he introduces new technologies for phantom limb pain and ultra-high-frequency peripheral stimulation. The session emphasizes the need for wider adoption of advanced waveforms, given their efficacy and reduced explant rates, particularly for underserved and complex pain populations.

Watch Now

NEWEST VIDEO

Watch Now

Dr. Robert Levy – The Closed Loop Revolution – Video Hero Slider

NEWEST VIDEO

The Closed Loop Revolution

This presentation explores the transformative impact of closed-loop spinal cord stimulation (SCS) using evoked compound action potentials (ECAPs). Unlike traditional open-loop systems, which blindly deliver constant stimulation despite anatomical or physiological changes, closed-loop technology continuously adjusts output in real time, maintaining optimal activation within a patient’s therapeutic window. Clinical trials, especially the EVOKE trial, demonstrated superior long-term outcomes, including pain relief, improved function, and reduced opioid use. The future of neuromodulation lies in expanding closed-loop applications to non-tonic waveforms like burst and high-frequency stimulation, enhancing personalization and effectiveness across diverse pain conditions.

Watch Now

Watch Now

(L) Dr. Robert Levy – Toward Development of Personalized Neuromodulation Therapy – Video Hero Slider

NEWEST VIDEOS

This talk outlines the emerging field of personalized neuromodulation, with a focus on closed-loop spinal cord stimulation using evoked compound action potentials (ECAPs). Unlike traditional open-loop systems, closed-loop SCS adapts in real-time to maintain optimal spinal cord activation, leading to more consistent pain relief and patient satisfaction. The speaker presents robust data from the EVOKE trial showing long-term efficacy and introduces the concept of the dose ratio (optimal at 1.4) as a personalized biomarker. The talk advocates for a shift from pain-only outcomes to holistic metrics and positions ECAP-guided therapy as a foundational step toward individualized neuromodulation.

Watch Now

Watch Video

Toward Development of Personalized Neuromodulation Therapy

(L) Dr. Robert Levy – Placebo Effect in Neuromodulation Therapy – Video Hero Slider

NEWEST VIDEO

Placebo Effect in Neuromodulation Therapy

This lecture explores the powerful role of the placebo effect in neuromodulation, challenging the perception that it undermines therapy efficacy. While placebo is a confounding factor in research, especially in pain trials, it can be a therapeutic asset in clinical practice. The speaker explains the neurobiology behind placebo and nocebo effects, outlines their impact on outcomes even in conditions like Parkinson's disease, and calls for ethical yet effective priming of patients to enhance treatment outcomes. Ultimately, placebo shouldn't discredit neuromodulation but should be understood, ethically managed in trials, and embraced in clinical care to maximize patient benefit.

Watch Now

Watch Now

Slide

growth becomes exponential and irreversible. He challenges the idea of hardware unification across companies and instead reframes singularity as a coming wave of revolutionary innovation. Highlighting breakthroughs in neurorestoration, brain-computer interfaces, optogenetics, and AI-driven performance enhancement, he envisions a future where neuromodulation reshapes mobility, cognition, and memory. From paralyzed patients walking again to implantable memory-enhancing technologies, Dr. Deer outlines how these advancements could transform pain management, disability care, and human potential—while cautioning about ethical implications and the “tribal” limitations of device brand loyalty.

Creating the Singularity where is neuromodulation taking us

Slide

This presentation explores the clinical value of 10 kHz high-frequency spinal cord stimulation (HF-SCS) for treating various chronic pain conditions, including non-surgical refractory back pain, diabetic peripheral neuropathy, and chronic abdominal pain. The speaker reviews pivotal studies demonstrating long-term pain relief and functional improvements, highlighting data integrity, trial design, and superior outcomes compared to traditional paresthesia-based systems. Additionally, he introduces new technologies for phantom limb pain and ultra-high-frequency peripheral stimulation. The session emphasizes the need for wider adoption of advanced waveforms, given their efficacy and reduced explant rates, particularly for underserved and complex pain populations.

High Frequency Stimulation Data Matters

Slide

This presentation explores the transformative impact of closed-loop spinal cord stimulation (SCS) using evoked compound action potentials (ECAPs). Unlike traditional open-loop systems, which blindly deliver constant stimulation despite anatomical or physiological changes, closed-loop technology continuously adjusts output in real time, maintaining optimal activation within a patient’s therapeutic window. Clinical trials, especially the EVOKE trial, demonstrated superior long-term outcomes, including pain relief, improved function, and reduced opioid use. The future of neuromodulation lies in expanding closed-loop applications to non-tonic waveforms like burst and high-frequency stimulation, enhancing personalization and effectiveness across diverse pain conditions.

The Closed Loop Revolution

Slide

Toward Development of Personalized Neuromodulation Therapy

This talk outlines the emerging field of personalized neuromodulation, with a focus on closed-loop spinal cord stimulation using evoked compound action potentials (ECAPs). Unlike traditional open-loop systems, closed-loop SCS adapts in real-time to maintain optimal spinal cord activation, leading to more consistent pain relief and patient satisfaction. The speaker presents robust data from the EVOKE trial showing long-term efficacy and introduces the concept of the dose ratio (optimal at 1.4) as a personalized biomarker. The talk advocates for a shift from pain-only outcomes to holistic metrics and positions ECAP-guided therapy as a foundational step toward individualized neuromodulation.

Slide

This lecture explores the powerful role of the placebo effect in neuromodulation, challenging the perception that it undermines therapy efficacy. While placebo is a confounding factor in research, especially in pain trials, it can be a therapeutic asset in clinical practice. The speaker explains the neurobiology behind placebo and nocebo effects, outlines their impact on outcomes even in conditions like Parkinson's disease, and calls for ethical yet effective priming of patients to enhance treatment outcomes. Ultimately, placebo shouldn't discredit neuromodulation but should be understood, ethically managed in trials, and embraced in clinical care to maximize patient benefit.

Placebo Effect in Neuromodulation Therapy

Recent Popular

3 Results found

Videos

Pro

Douglas P. Beall

November 17, 2021

Beall – Intraosseous Basivertebral Nerve Ablation Randomized Control Trial: 24-Month Results vs Conservative Care

Dr. Douglas P. Beall discusses intraosseous basivertebral nerve ablation in a randomized control trial). Specifically, he discusses the 24-month results from this INTRACEPT study in comparison with conservative care (or non-surgical management). This surgery...

$3.75

Pro

Kenneth B. Chapman

November 17, 2021

Chapman – Dorsal Root Ganglion Stimulation for Low Back Pain

Dr. Kenneth B. Chapman discusses dorsal root ganglion (DRG) stimulation for low back pain. Dr. Chapman describes the results of his clinical research on this topic. This DRG stimulation results in impressive improvements across...

$3.75

Pro

November 17, 2021

Erdine – Ethics & Interventional Pain

Dr. Serdar Erdine discusses ethics and interventional pain. He describes the four principles of ethics in medicine: autonomy, non-maleficence, beneficence, and justice. He says there is a crisis in pain care, and it is...

$3.75